RT Journal Article
SR Electronic
T1 PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 97S
OP 104S
DO 10.2967/jnumed.115.170167
VO 57
IS Supplement 3
A1 Kulkarni, Harshad R.
A1 Singh, Aviral
A1 Schuchardt, Christiane
A1 Niepsch, Karin
A1 Sayeg, Manal
A1 Leshch, Yevgeniy
A1 Wester, Hans-Juergen
A1 Baum, Richard P.
YR 2016
UL http://jnm.snmjournals.org/content/57/Supplement_3/97S.abstract
AB A potential milestone in personalized nuclear medicine is theranostics of metastatic castration-resistant prostate cancer (mCRPC) based on molecular imaging using PET/CT with 68Ga-labeled prostate-specific membrane antigen (PSMA) ligands and molecular radiotherapy using PSMA-targeted radioligand therapy (PRLT) with 177Lu-PSMA ligands. 68Ga-PSMA PET/CT enables accurate detection of mCRPC lesions with high diagnostic sensitivity and specificity and provides quantitative and reproducible data that can be used to select patients for PRLT and therapeutic monitoring. Our comprehensive experience over the last 3 years using different radioligands indicates that PRLT is highly effective for the treatment of mCRPC, even in advanced cases, and potentially lends a significant benefit to overall and progression-free survival. Additionally, significant improvement in clinical symptoms and excellent palliation of pain can be achieved.